to Extend the Healthspan
At Rejuvenation we're using mRNA to treat fatal diseases of aging
Recent Advances Toward Clinical Trials
Benefitting from our TERT mRNA telomere extension platform technology, Rejuvenation’s pipeline encompasses multiple organ systems as well as cell therapies. These programs target fatal diseases with high unmet medical need.
Founder & CEO, Stanford PhD, Co-inventor, Decade of experience with mRNA for therapeutic applications. Thesis title: Telomere extension to extend human healthspan.
Founder & COO, Stanford PhD, Decade of experience in genetics and epigenetics of cellular reprogramming.
Research Fellow, MD, MSc, PhD, CTBS, Clinical and Preclinical Development at Boehringer Ingelheim and Gilead. Postdoc at Yale University on novel roles of ion transport proteins.
Research Scientist, Postdoc at Stanford University on the proteomics of aging in the liver and brain, PhD in Biophysics at UT Southwestern on neurotransmitter release.
Helen M. Blau
Founder & Advisor, Co-inventor, Professor at Stanford University, discovered that short telomeres underlie the fatal etiology of multiple monogenic diseases.
Life Science Research Associate, MSc in Biotechnology.
Bioengineering Research Associate, BSc in Bioengineering
Robin E. Holbrook
Director of Finance and Administration, Stanford AB in Cultural Anthropology, 30+ years of F&A experience supporting research excellence at Stanford School of Medicine.
Employment inquiries: firstname.lastname@example.org
Investor inquiries: email@example.com
General inquiries: firstname.lastname@example.org